-Live Mint Court says legal, ethical issues involved; directs govt to monitor and regulate clinical trials of all experimental drugs  The Supreme Court directed the health ministry to monitor and regulate all clinical trials of experimental drugs in the country until further notice and observed that unregulated trials have caused “havoc”. The apex court order on Thursday revoked the power of the Central Drugs Standard Control Organization under the Drugs Controller General of...

-The Economic Times The environment ministry has simplified the procedures for granting clearances to special economic zones as it seeks to shed the anti-industry image. A recent order issued by the environment ministry states that the environmental clearance process for SEZs will now follow the system laid out for National Industrial and Manufacturing Zones under the National Manufacturing Policy 2011. Under the new system, the central and state governments will delegate power to...

-Live Mint While natural disasters grab our attention, everyday events like illness drag most people into poverty  In a small town of Gujarat, I met Chandibai, a woman, about 50 years of age. Fifteen years previously, her husband, Gokalji, had owned a general-purpose shop in the town centre. The family also owned a house and some agricultural land. In 1989, Gokalji developed an illness that confined him to bed, sometimes at home...

-The Economic Times MUMBAI: A drug maker found overcharging will have to shell out the entire sales revenue of the medicine from the date of its launch as penalty, according to a directive issued by the country's drug price regulator. "If a company has not been booked for overcharging for selling the product without price approval, if any, pertaining to the period prior to fixation of the price of the said formulation,...

-The Times of India Medicines in India may not be sold under brand names in the near future. In its biggest move to push generic drugs and do away with brand names, the Union health ministry has ordered states to stop issuing licence for the manufacture or sale of drugs on the basis of their brand name. All pharmaceutical firms applying for licence to market or manufacture fixed dose combination (FDC) drugs will...